Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease

American Journal of Cardiology

Volumn 95, Issue 2, 2005, Pages 236-240

  Azar, Rabih R ^a,c   Badaoui, Georges ^a   Sarkis, Antoine ^a   Kassab, Roland ^a   Salamé, Elie ^a   Klaymé, Samira ^b   Naman, Roger ^b   Germanos, Mirna ^c  

^a Division of Cardiology   (Lebanon)

^b Laboratory of Histocompatibility

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MARKER; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INHIBITION KINETICS; MALE; PATIENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; C-REACTIVE PROTEIN; CD40 LIGAND; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TYROSINE;

EID: 11844297296     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.08.093     Document Type: Article

References (19)

1. R.R. Azar, R.G. McKay, F.J. Kiernan, B. Seecharran, Y.J. Feng, D.B. Fram, A.H.B. Wu, D.D. Waters Coronary angioplasty induces a systemic inflammatory response Am J Cardiol 80 1997 1476 1478
2. A. Gaspardone, F. Crea, F. Versaci, F. Tomai, A. Pellegrino, L. Chiariello, P.A. Gioffre Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina Am J Cardiol 82 1998 515 518
3. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (RRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
4. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis Circulation 96 1997 1445 1453
5. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
6. A.W. Chan, D.L. Bhatt, D.P. Chew, M.J. Quinn, D.J. Moliterno, E.J. Topol, S.G. Ellis Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696
7. A.W. Chan, D. Bhatt, D.P. Chew, J. Reginelli, J.P. Schneider, E.J. Topol, S.G. Ellis Relation of inflammation and benefit of statins after percutaneous coronary interventions Circulation 107 2003 1750 1756
8. P. André, L. Nannizzi-Alaimo, S.K. Prasad, D.R. Phillips Platelet-derived CD40L The switch-hitting player of cardiovascular disease Circulation 106 2002 896 899
9. U. Schonbeck, P. Libby The CD40/CD154 receptor/ligand dyad Cell Mol Life Sci 58 2001 4 43
10. V. Henn, J. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster, G. Muller-Berghaus, R.A. Kroczek CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 1998 591 594
11. P. André, S.K. Prasad, C.V. Denis, M. He, J.M. Papalia, R.O. Hynes, D.R. Phillips, D.D. Wagner CD40L stabilizes arterial thrombi by a beta-3 integrin-dependent mechanism Nat Med 8 2002 247 252
12. N. Nannizzi-Alaimo, V.L. Alves, D.R. Phillips Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of sCD40l during platelet stimulation Circulation 107 2003 1123 1128
13. C. Weber, T.A. Springer Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alpha-IIb beta-3 and stimulated by platelet activating factor J Clin Invest 100 1997 2085 2093
14. J. Sarma, C.A. Laan, S. Alam, A. Jha, K.A.A. Fox, I. Dransfield Increased platelet binding to circulating monocytes in acute coronary syndromes Circulation 105 2002 2166 2171
15. M. Schwarz, T. Nordt, C. Bode, K. Peter The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2) Thromb Res 107 2002 121 128
16. J.K. Mickelson, M.N. Ali, N.S. Kleiman, N.M. Lakkis, T.W. Chow, B.J. Hughes, C.W. Smith Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty J Am Coll Cardiol 33 1999 97 106
17. A.M. Lincoff, D.J. Kereiakes, M.A. Mascelli, L.I. Deckelbaum, E.S. Barnathan, K.K. Patel, B. Frederick, M.T. Nakada, E.J. Topol Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization Circulation 104 2001 163 167
18. G. Liuzzo, A. Buffon, L.M. Biasucci, J.R. Gallimore, G. Caligiuri, A. Vitelli, S. Altamura, G. Ciliberto, A.G. Rebuzzi, F. Crea Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina Circulation 98 1998 2370 2376
19. P.O. Bonetti, L.O. Lerman, C. Napoli, A. Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J 24 2003 225 248